TY - JOUR
T1 - Acute and chronic graft-versus-host disease
AU - Vogelsang, G. B.
PY - 1993/1/1
Y1 - 1993/1/1
N2 - Acute graft-versus-host disease is a two-step process. First, allorecognition of histocompatibility antigen activates T lymphocytes, which releases several cytokines, including interleukin-1 and tumor necrosis factor. Understanding of this activity resulted in new therapeutic approaches. Chronic graft-versus-host disease remains a very frequent and difficult problem to treat. Thalidomide was introduced as therapy for chronic graft-versus-host disease. Although basic research reported this year had no common theme, progress, was made in many areas.
AB - Acute graft-versus-host disease is a two-step process. First, allorecognition of histocompatibility antigen activates T lymphocytes, which releases several cytokines, including interleukin-1 and tumor necrosis factor. Understanding of this activity resulted in new therapeutic approaches. Chronic graft-versus-host disease remains a very frequent and difficult problem to treat. Thalidomide was introduced as therapy for chronic graft-versus-host disease. Although basic research reported this year had no common theme, progress, was made in many areas.
UR - http://www.scopus.com/inward/record.url?scp=0027516895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027516895&partnerID=8YFLogxK
U2 - 10.1097/00001622-199303000-00005
DO - 10.1097/00001622-199303000-00005
M3 - Review article
C2 - 8457614
AN - SCOPUS:0027516895
SN - 1040-8746
VL - 5
SP - 276
EP - 281
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 2
ER -